News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US Warns Novartis Corporation Generic Unit on Plant Problems
August 26, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Aug 26 (Reuters) - U.S. regulators have warned Novartis AG's generic drug unit Sandoz about manufacturing problems at a North Carolina plant, a letter released on Tuesday said.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
FDA
CAR-T Developers Will Need Randomized Trials as FDA Eyes Tighter Approval Requirements
December 9, 2025
·
2 min read
·
Tristan Manalac
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
·
3 min read
·
Jennifer Smith-Parker
Regulatory
In Change That Pushed Pazdur Out, FDA May Lower Clinical Trial Requirements
December 5, 2025
·
2 min read
·
Dan Samorodnitsky
Regulatory
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals
December 5, 2025
·
2 min read
·
Tristan Manalac
